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WHY WAS IT IMPORTANT TO DO THIS COCHRANE REVIEW?1
Asthma is a chronic respiratory disease characterised by reversible airflow obstruction, with periods
of relative control and episodes of deterioration referred to as exacerbations. Exacerbations range in
severity from mild to life-threatening and may require emergency department management and
brief hospitalisations. Although rare, admissions to intensive care, mechanical ventilation and deaths
from severe acute asthma exacerbations do still occur2.
In the UK, the condition affects one in 11 children; a child is admitted to hospital every 20 minutes
due to asthma3. Options for treating exacerbations include inhaled bronchodilators such as
salbutamol and ipratropium, systemic steroids and other supportive measures such as oxygen4.
Magnesium sulfate has been proposed as a possible additive treatment in acute asthma, and has
been shown to be effective in severe acute asthma when delivered intravenously5. However, there is
more uncertainty about the role of inhaled or nebulised magnesium sulfate. British Thoracic
Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) Asthma Guidelines do not
recommend its use at all in adults and only if other treatments have failed in the context of a severe
asthma exacerbation of short duration in children3.
A previous version of this review published in 2012 found insufficient evidence, particularly in
children, to either clearly support or refute the use of inhaled magnesium sulfate. Several large trials
have been published in recent years, including studies in children, necessitating an update of this
review1. The published review used established Cochrane methods and includes studies in all ages;
data relating to children are presented here.
WHAT WERE THE OBJECTIVES OF THE REVIEW?
The aim of the review was to assess whether giving inhaled magnesium for acute asthma is (1) safe,
(2) whether it improves lung function, (3) reduces the need for admission and (4) reduces asthma
symptom/severity scores.
WHAT WAS THE EVIDENCE BASE OF THE REVIEW?
We included eight randomised controlled trials involving a total 1247 children in the review.
Populations, interventions and procedures varied across the eight studies. We chose to extract
outcomes at, or as close as possible to, 60 minutes post-baseline. We identified three main
comparisons:
1. Nebulised salbutamol and ipratropium plus magnesium sulfate versus nebulised salbutamol and
ipratropium alone (two studies)
2. Nebulised salbutamol plus magnesium sulfate versus nebulised salbutamol alone (five studies)
3. Nebulised magnesium sulfate alone versus nebulised salbutamol alone (one study).
Most of the studies, when specified, allowed co-interventions including systemic corticosteroids.
Sample sizes ranged from 17 to >500 participants with the larger trials conducted more recently.
Children ranged from two to 17 years of age and had predominantly moderate to severe acute
asthma, variably defined, at the time of study enrolment (Table 1).
While we judged most trials to be at low risk of bias overall, there was uncertainty about selection
bias in four trials and bias related to performance and detection in three trials. We considered two
trials to be at high risk for reporting bias. Our confidence in the results is reduced by the limited
number of meta-analyses we were able to perform, largely due to heterogeneity of the interventions
and outcomes reported.
WHAT WERE THE FINDINGS OF THE REVIEW?
Percent predicted forced expiratory volume in one second (FEV1) was reported by one study,
favouring the addition of magnesium to salbutamol, but the confidence interval (CI) suggests no
statistical difference (mean difference 8.10, 95% CI -3.03 to 19.23; n = 62). A further study
investigating the same comparison reported peak expiratory flow (PEF) and while the addition of
magnesium is again favoured, the result is uncertain (MD 11.90 L/min, 95% CI -6.86 to 30.66; n = 80).
No significant difference was found in three trials comparing magnesium to other non-magnesium
treatments for admission to hospital (Risk ratio 0.97, 95% CI 0.92 to 1.02; n = 670). One study
reported clinical severity using the Yung Asthma Severity Score (ASS)6. The result favoured the
magnesium group at 60 minutes, but this is unlikely to reflect a clinically important difference, and
again, the CI includes zero (MD -0.17, 95% CI -0.35, 0.02; n = 472), indicating no statistical difference
between groups. Serious adverse events were rare but slightly less frequent in the magnesium group
(Risk difference -0.031, 95% CI -0.058 to -0.004; n = 569).
Of note, the largest study in children reported subgroup analysis for their primary outcome, ASS,
investigating whether participants with a more severe asthma exacerbation or an exacerbation of
shorter duration derived more benefit from the addition of nebulised magnesium. Although not
powered to detect a difference, the study results support this hypothesis7.
WHAT ARE THE IMPLICATIONS OF THIS REVIEW FOR PRACTICE AND FOR RESEARCH?
Treatment with nebulised magnesium sulfate is likely to be safe and may result in modest additional
benefits for children when added to inhaled salbutamol and ipratropium bromide; however, our
confidence in the evidence is low and there remains substantial uncertainty. Evidence from one
large trial suggests children with a more severe exacerbation or shorter duration of symptoms may
experience a greater benefit; this is reflected in current guidance (BTS/SIGN)3,7. Due to heterogeneity
of outcome measures we were able to perform very limited meta-analyses and unable to implement
our planned subgroup analysis for severity. There is little evidence regarding the use of nebulised
magnesium sulfate as an alternative to salbutamol and it is unlikely that future trials will address this
question directly.
Further placebo-controlled trials in participants with severe asthma exacerbations or with symptoms
of short duration not responding to standard maximal treatment may help establish if nebulised
magnesium sulfate has a role in this context. However, the accumulating evidence suggests that a
substantial benefit may be unlikely. Trials comparing the safety and efficacy of nebulised magnesium
to intravenous magnesium are also of interest.
TABLE 1
ID Country Total
n
Age range
(years)
Inclusion Magnesium
regimen
Co-treatments
Turker
20178
Turkey 100 3 to 15 Moderate
asthma
exacerbation
Three doses at
20 minutes
intervals
Salbutamol,
prednisolone
Alansari
20159
Qatar 400 2 to 14 Moderate to
severe asthma
exacerbation
Three doses
20 minutes
intervals
Salbutamol,
ipratropium,
prednisolone
Mohamm
edzadeh
201410
Iran 80 5 to 14 Moderate to
severe asthma
exacerbation
Three doses at
20 minutes
intervals
Not stated
Powell
20137
UK 508 2 to 16 Severe asthma
exacerbation
after
conventional
treatment
Three doses at
20 minutes
intervals
Hospital-
defined
standard
treatment
Ashtekar
200811
UK 17 2 to 16 Severe asthma
exacerbation
Three doses at
20 minutes
intervals
Ipratropium,
salbutamol,
prednisolone
Khashabi
200812
Iran 40 Mean 3.55 “Asthmatic
children”
Two doses of
(interval
unclear)
Salbutamol;
other co-
treatments not
stated
Mahajan
200413
USA 62 5 to 17 Acute asthma
exacerbation,
FEV1 between
45% and 75%
predicted
One dose Salbutamol,
prednisolone
Meral
199614
Turkey 40 “Paediatric” PEF decreased
by ≥ 25%. 
One dose Salbutamol
(control group
only)
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